MedTrace Logo

Observational Small Intestine and Blood Fingerprint (SmIle) Study in Parkinson's Disease

NCT06003608 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-01-31

No results posted yet for this study

Summary

Observational cross-sectional study in PD patients and healthy controls (HC) using an investigational medical device consisting of a passive small intestine microbiome aspiration (SIMBA) system (capsule) that is ingested orally and recovered together with the stools (home recovery) together with blood sampling (during the onsite visit).

Conditions

  • Parkinson Disease

Interventions

DEVICE

Fluid biopsy capsule

Ingestion of two SIMBA capsules

DRUG

Levodopa-Carbidopa Immediate Release

Single dose, Levodopa-Carbidopa Immediate Release

Sponsors & Collaborators

  • MRM Health N.V.

    collaborator UNKNOWN

  • Nimble Science Ltd.

    lead INDUSTRY

Principal Investigators

  • Davide Martino, MD PHD · University of Calgary

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-19
Primary Completion
2025-02-28
Completion
2025-02-28

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06003608 on ClinicalTrials.gov